Date: 2017-07-24
Type of information: Development agreement
Compound: NKTR-358
Company: Eli Lilly (USA - IN) Nektar Therapeutics (USA - CA)
Therapeutic area: Autoimmune diseases – Inflammatory diseases
Type agreement: development - commercialisation
Action mechanism:
- immunotherapy product. NKTR-358 works by optimally targeting the interleukin-2 receptor complex in order to stimulate proliferation and activation of regulatory T cells. By increasing the number of regulatory T cells, the pathogenic auto-reactive T cells can be controlled and the proper balance of effector and regulatory T cells can be achieved to restore the body's self-tolerance mechanisms.
- In preclinical studies, NKTR-358 has demonstrated that it could suppress antigen-driven inflammation in a model of cutaneous hypersensitivity. NKTR-358 has also shown that it reduces markers of progression in a mouse model of systemic lupus erythematosus.
- NKTR-358 is being developed as a once or twice-monthly self-administered injection for a number of auto-immune diseases.
Disease:
Details:
- • On July 24, 2017, Eli Lilly and Nektar Therapeutics have announced a strategic collaboration to co-develop NKTR-358, a novel immunological therapy discovered by Nektar. NKTR-358 targets the interleukin (IL-2) receptor complex in the body in order to stimulate proliferation of powerful inhibitory immune cells known as regulatory T cells.
- By activating these cells, NKTR-358 may act to bring the immune system back into balance. The product has achieved first human dose in Phase 1 clinical development in March of 2017, has the potential to treat a number of autoimmune and other chronic inflammatory conditions.
Financial terms:
- Under the terms of the agreement, Nektar will receive an initial payment of $150 million and is eligible for up to $250 million in additional development and regulatory milestones. Lilly and Nektar will co-develop NKTR-358 with Nektar responsible for completing Phase 1 clinical development. The parties will share Phase 2 development costs 75 percent Lilly and 25 percent Nektar. Nektar will have the option to participate in Phase 3 development on an indication-by-indication basis.
- Nektar has the opportunity to receive double-digit royalties that increase commensurate with their Phase 3 investment and product sales. Lilly will be responsible for all costs of global commercialization. Nektar will have an option to co-promote in the U.S. under certain conditions.
Latest news:
Is general: Yes
